ArticleHealth science reports2025
Serum Hepcidin Levels in Breast Cancer Patients: Investigating the Correlation to Tumor Stage-A Cross-Sectional Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic Significance of Hemogram Parameters in Non-Muscle Invasive Bladder Cancer: A Comprehensive Retrospective Analysis.Medicina (Kaunas, Lithuania) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Breast cancer is one of the most common types of cancer worldwide. Hepcidin is a liver-produced hormone playing a key role in the regulation of iron levels in the body. Studies have shown that hepcidin is upregulated in many diseases and inflammatory conditions, including cancers. This study paper aims to assess serum hepcidin in patients with breast cancer and to study its correlation with tumor stage. Methods: A total of 39 breast cancer women and 25 healthy controls were included in the study. Serum hepcidin levels were measured using the ELISA method. Other tumor-related parameters including Cancer Antigen 15-3 (CA 15-3), Iron (Fe), C-Reactive Protein (CRP) and the complete blood count (CBC) were also assessed. Results: This study showed Furthermore, this study found a positive correlation a significant increase in hepcidin levels in breast cancer patients compared to healthy controls ( Conclusion: These findings suggest that serum hepcidin may serve as a potential biomarker to monitor disease progression in breast cancer patients. CRP could be a positive-regulator for hepcidin in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.